Transcranial Magnetic Stimulation (TMS) for Trigeminal Neuralgia

Facial Pain Clinical Trial

— TGN  

Official title:

An Investigation of Transcranial Magnetic Stimulation (TMS) for Trigeminal Neuralgia (TGN)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04120129
• Other study ID #: 19-371
• Status: Recruiting
• Phase: N/A
• Start date: August 1, 2020
• Est. completion date: June 2021

Study information

• Verified date: November 2020
• Source: Carilion Clinic
• Contact: Mark Witcher, MD, PhD
• Phone: 540-224-5170
• Email: mrwitcher[@]carilionclinic.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective is to establish the feasibility of using TMS for COFP pain management in the interim period before surgery. This will be investigated by comparing the non-intervention group's self-reported pain to those who recieved TMS at several timepoints.

Description:

Participants will be randomized to either receive transcranial magnetic stimulation (TMS), Sham-TMS (a non-therapeutic TMS coil which sounds and feels similar to normal TMS), or standard treatment during the weeks of wait time before surgery for chronic orofacial pain (COFP). TMS is a noninvasive, painless magnetic device which, when applied to the head for a few minutes, has been shown to reduce pain in people with COFP. The sham TMS is a sub-therapeutic level of magnetcic stimulation which makes the same sound as normal TMS and causes a similar tingling of the skin. Both those who receive this new pain intervention and those who do not will be asked to fill out a short online survey about their pain at several points during the study. The survey takes about 10 minutes to fill out and each of the 5 TMS sessions last 10 minutes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 51
• Est. completion date: June 2021
• Est. primary completion date: February 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Documented diagnosis of classic trigeminal neuralgia or persisten idiopathic facial pain
• Considered an appropriate candidate for surgical or stereotactic intervention - microvascular decompression or stereotactic radiosurgery- ( includes factors such as overall health, chronic medication, comorbidities) and patient preference
• Between ages 18-100
• Able to participate in 5 consecutive TMS treatments
• Has at least 3 weeks between pre-op visit and scheduled date of surgery
• Able to provide consent and complete online questionnaires on their own

Exclusion Criteria:

• Multiple Sclerosis or trauma-related etiology of facial pain (i.e. secondary facial pain)
• contraindication to TMS, per device guidelines:

Metallic implant in or near head Implanted stimulator on or near head recent suicidal ideation history of epilepsy, stroke, or unexplained seizure

• Need for urgent/emergent surgical decompression.

Related Conditions & MeSH terms

• Facial Pain
• Neuralgia
• Trigeminal Neuralgia

Intervention

Device:
• TMS
Transcranial Magnetic Stimulation (TMS) is a noninvasive brain stimulation technique which produces short pulsatile magnetic fields (similar to that of an MRI) via two extracranial, figure 8-shaped electric coils which can induce a small, temporary, electric current in the brain currently approved and used for depression.
• sham TMS coil
The sham TMS does cause some stimulation to the participant so that the participants get the sensation of treatment without any cortical excitation that TMS delivers. The sensation experienced is similar to the muscle twitching or finger tapping experienced by TMS participants.

Locations

Country	Name	City	State
United States	Institute for Orthopedics and Neurosciences	Roanoke	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
Carilion Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changed Pain assessed by self reported measures: Short-form McGill Pain Questionnaire 2 (SF-MPQ-2)	The primary objective is to establish the effectiveness of TMS for COFP pain management in the interim period before surgery. This will be investigated by comparing the non-intervention group's self-reported pain to those who received TMS at several timepoints. Short-form McGill Pain Questionnaire 2 (SF-MPQ-2)will be used. The scale asks participants to identify their pain level across body areas and total from 0-10 (0 being none & 10 worst possible)	7 months
Secondary	Length of altered pain	A secondary objective is to establish how long the effects of TMS last. This will be done by comparing self-reported pain scores prior to TMS, after TMS and at several timepoints thereafter in those who recieved the treatment. Short-form McGill Pain Questionnaire 2 (SF-MPQ-2) will be used. The scale asks participants to identify their pain level across body areas and total from 0-10 (0 being none & 10 worst possible)	7 months